David A. Siegel Pliant Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 149,500 shares of PLRX stock, worth $1.61 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

149,500

Previous 92,600 61.45%

Holding current value

$1.61 Million

Previous $1.68 Million 32.88%

% of portfolio

0.01%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$14.14 - $19.59 $804,566 - $1.11 Million	56,900 Added 61.45%	149,500 $2.23 Million
Q4 2023 Feb 14, 2024	SELL	$12.85 - $19.15 $884,080 - $1.32 Million	-68,800 Reduced 42.63%	92,600 $1.68 Million
Q3 2023 Nov 14, 2023	SELL	$14.58 - $20.15 $497,178 - $687,115	-34,100 Reduced 17.44%	161,400 $2.8 Million
Q2 2023 Aug 14, 2023	SELL	$18.12 - $30.56 $1.32 Million - $2.22 Million	-72,800 Reduced 27.13%	195,500 $3.54 Million
Q1 2023 May 15, 2023	BUY	$18.73 - $36.26 $1.71 Million - $3.3 Million	91,100 Added 51.41%	268,300 $7.14 Million

Q4 2022 Feb 14, 2023	BUY	$17.0 - $25.43 $1.3 Million - $1.95 Million	76,600 Added 76.14%	177,200 $3.43 Million
Q3 2022 Nov 14, 2022	BUY	$7.67 - $24.23 $348,218 - $1.1 Million	45,400 Added 82.25%	100,600 $2.1 Million
Q2 2022 Aug 15, 2022	SELL	$4.11 - $8.75 $90,009 - $191,625	-21,900 Reduced 28.4%	55,200 $442,000
Q1 2022 May 16, 2022	BUY	$7.01 - $14.1 $222,217 - $446,970	31,700 Added 69.82%	77,100 $540,000
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.26 $557,058 - $829,004	45,400 New	45,400 $613,000

Others Institutions Holding PLRX

# of Institutions

148

Shares Held

63.8M

Call Options Held

417K

Put Options Held

123K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $523M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account